Latest Articles

  • Vaccine hesitancy: Where are we heading?

    Sherif Beniameen Mossad, MD
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 21-26;
    • DOI: https://doi.org/10.3949/ccjm.93a.25104

    • Vaccination recently was hailed as one of the top 10 public health achievements of the 20th century; now, the World Health Organization lists vaccine hesitancy among the top 10 threats to global health.

  • Pseudoxanthoma elasticum

    Kathleen Kramer, MD, Sama Alazawi, DO and Rudy Schmiedecke, MD
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 13-14;
    • DOI: https://doi.org/10.3949/ccjm.93a.25021

    • The patient presented for evaluation of yellowish plaques on her neck that had been present since childhood.

  • TOC Icon

    A young woman with Kallmann syndrome and acute neurologic symptoms

    Jumaina F. Ali, MBChB, Adhithya Sankar, MBChB, PhD, Mohammed S. O. Ahmed, MBBS, MSc, Mark Woodward, BSc (Hons), MBChB and Akheel A. Syed, MBBS, PhD
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 29-34;
    • DOI: https://doi.org/10.3949/ccjm.93a.25010

    • Diagnoses considered on initial presentation included conditions that present with stroke-like symptoms such as seizure, hemiplegic migraine, transient ischemic attack, and brain tumor.

  • Update on antiobesity pharmacotherapy in adults: Current and emerging options

    Farah Ziyadeh, MD, Sara Saliba, MD, RD, Dania Salih Bacha, MD, Yael Mauer, MD, MPH, Marcio L. Griebeler, MD, DABOM and Bartolome Burguera, MD, PhD
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 36-46;
    • DOI: https://doi.org/10.3949/ccjm.93a.24112

    • The authors review antiobesity medications that are currently available or under investigation and discuss how to personalize obesity treatment.

  • Atrial fibrillation in patients with obesity: How can we optimize management?

    Asim Kichloo, MD, Ivan Magallanes Marrufo, MPH and Suhaib Andrabi, MD
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 17-20;
    • DOI: https://doi.org/10.3949/ccjm.93a.25032

    • Heart rate and rhythm control therapies often must be adjusted when treating patients with obesity, while other measures can reduce the onset or recurrence of atrial fibrillation.

  • More on the myths and perceived magic of corticosteroids

    Brian F. Mandell, MD, PhD
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 6-7;
    • DOI: https://doi.org/10.3949/ccjm.93b.01026

    • It is widely accepted that corticosteroids can partially prevent infusion reactions to intravenous diagnostic and therapeutic agents, but evidence to support this concept is scant.

  • Multicentric reticulohistiocytosis

    Atul Khasnis, MD, MS and Joseph M. Dyer, DO
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 9-11;
    • DOI: https://doi.org/10.3949/ccjm.93a.24124

    • A 58-year-old man presented with a 2-month history of joint pain and swelling and a rash.

  • Do corticosteroids prevent reactions to infusions of contrast, monoclonal antibodies, or chemotherapy?

    CME Image
    Dylan T. Timberlake, MD, Sushmitha Boppana, MD and James Fernandez, MD, PhD
    • Cleveland Clinic Journal of Medicine January 2026, 93 (1) 47-53;
    • DOI: https://doi.org/10.3949/ccjm.93a.25026

    • The data and recommendations about corticosteroid pretreatment vary by medication class and the individual medication, necessitating a medication- and patient-specific approach.

  • Should I consider low-dose rivaroxaban (2.5 mg) for my patient with peripheral artery disease?

    Pranay Marlecha, MD, Deborah Hornacek, MD and Pulkit Chaudhury, MD, MS
    • Cleveland Clinic Journal of Medicine December 2025, 92 (12) 742-744;
    • DOI: https://doi.org/10.3949/ccjm.92a.25065

    • For patients with high ischemic risk, rivaroxaban 2.5 mg twice daily with aspirin 81 or 100 mg daily is a proven strategy to reduce major cardiovascular and limb events.

  • LADA: A case for starting insulin therapy at diagnosis

    Byron J. Hoogwerf, MD
    • Cleveland Clinic Journal of Medicine December 2025, 92 (12) 764-766;
    • DOI: https://doi.org/10.3949/ccjm.92a.25084

    • The author discusses factors that support starting insulin therapy at diagnosis in all patients with latent autoimmune diabetes in adults.

Previous
Next